Follow us on

Q of the week

Q: Do clinical trials ever go wrong?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 12:12:20
Managing Clinical Trials   by  on 2010-07-15 16:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 10:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 10:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 09:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 09:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 11:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 11:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 01:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 01:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-20 19:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-18 23:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-18 22:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 07:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-04 20:52:16
CONSORT III (2010)   by  on 2010-03-29 12:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 12:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 14:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-25 20:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 12:12:14
 Subject :PhRMA: More than 800 Medicines and Vaccines in Clinical Trials for Can.. 2010-01-10 20:26:15 
GCP HelpDesk
Joined: 2009-06-18 15:31:58
Posts: 62
Subject :PhRMA: More than 800 Medicines and Vaccines in Clinical Trials for Cancer

Dear Friends,

Few things cause patients more fear and uncertainty than a cancer diagnosis. But today because of a steady stream of new and improved medicines and treatments—cancer increasingly can be managed and even beaten. America’s pharmaceutical research and biotechnology companies are responding. Pharmaceutical researchers are now working on 861 medicines for cancer. Many are high-tech weapons to fight the disease, while some involve innovative research on using existing medicines in new ways. The medicines in development—all in either clinical trials or under Food and Drug Administration review— include 122 for lung cancer, the leading cause of cancer death in the United States; 106 for breast cancer, which is expected to strike more than 180,000 American women each year; 103 for prostate cancer, which is expected to kill more than 28,000 American men each year; and 70 for colorectal cancer, the third most common cancer in both men and women in USA. Additional medicines target brain cancer, kidney cancer, leukemia, ovarian cancer, pancreatic cancer, skin cancer, and others. In addition, companies are working on medicines to improve the quality of life for cancer patients. America’s pharmaceutical research companies are working on many new cutting edge approaches to fight cancer. They include:

  • A medicine that inhibits production of a protein that may interfere with the effectiveness of chemotherapy.
  • A drug that delivers a synthetic version of a substance derived from scorpions directly to brain tumor cells.
  • A medicine designed to induce a powerful immune response to melanoma.
  • A potential first-line treatment (meaning it’s given to patients before any other treatment) and first-in-class medicine designed to target specific cancer cells and kill them, then activate the patient’s general immune system to destroy any remaining cancer cells.
  • One therapy in development uses new nanotechnology that enhances the delivery of medicine to the patient, overcoming obstacles in existing treatments.

Click here for the complete report.

Kind regards,

IP Logged
Last Edited On: 2010-01-10 20:26:15 By GCP HelpDesk for the Reason
GCP HelpDesk
Page # 

Powered by ccBoard